ArticleIBRO neuroscience reports2025
Electroacupuncture enhances nerve regeneration and functional recovery in a rat model of median nerve transection.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the therapeutic efficacy and underlying mechanisms of electroacupuncture (EA) in promoting peripheral nerve regeneration following delayed repair of a median nerve transection in a rat model. Methods: Thirty male Sprague-Dawley rats were randomly assigned to five groups: sham operation, model (1- and 2-weeks post-transection), and EA treatment (1- and 2-weeks post-repair). Median nerve transection was performed, followed by delayed microsurgical repair. EA was applied at Jianyu (LI15) and Neiguan (PC6) acupoints following nerve repair. Nerve regeneration and tissue response were evaluated through histological staining (Hematoxylin and Eosin [H&E], Luxol Fast Blue [LFB], Masson's Trichrome [Masson]), immunofluorescence (S100β, Sox10), western blotting (phosphorylated phosphoinositide 3-kinase [p-PI3K], receptor for advanced glycation end products [RAGE], triggering receptor expressed on myeloid cells 2 [TREM2]), enzyme-linked immunosorbent assay (ELISA; interleukin-6 [IL-6], C-X-C motif chemokine ligand 3 [CXCL3], matrix metalloproteinase-3 [MMP3], reactive oxygen species [ROS], superoxide dismutase [SOD], malondialdehyde [MDA]), and transcriptome sequencing with gene set enrichment analysis (GSEA). Results: EA significantly enhanced axonal regeneration and remyelination, reduced inflammatory infiltration, and suppressed fibrotic collagen deposition. EA treatment markedly downregulated p-PI3K and RAGE expression and upregulated TREM2, indicating inhibition of inflammatory signaling and promotion of M2 macrophage polarization. Serum biomarkers showed reduced levels of IL-6, ROS, and MDA, along with increased SOD activity. Transcriptomic analysis revealed EA-induced activation of reparative and metabolic pathways, including lysosome function, endocytosis, and protein processing, while reversing injury-induced suppression of oxidative phosphorylation and ribosomal function. Conclusion: EA facilitates peripheral nerve regeneration through multi-target regulation of inflammation, oxidative stress, and neuroglial activity. These findings support the translational potential of EA as a complementary therapeutic strategy following nerve repair for upper limb peripheral nerve injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.